1	Postoperative Karnofsky performance status prediction in
2	patients with IDH wild-type glioblastoma: a multimodal
3	approach integrating clinical and deep imaging features
4	Tomoki Sasagasako, MD, ^{1,2} Akihiko Ueda, MD, PhD, ² Yohei Mineharu, MD, PhD, ³ Yusuke
5	Mochizuki ⁴ , Souichiro Doi ⁴ , Silsu Park, MD, ¹ Yukinori Terada, MD, PhD, ¹ Noritaka Sano, MD,
6	PhD, ¹ Masahiro Tanji, MD, PhD, ¹ Yoshiki Arakawa, MD, PhD, ¹ Yasushi Okuno, PhD ^{2,3}
7	
8	Affiliations:
9	¹ Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
10	² Department of Biomedical Data Intelligence, Kyoto University Graduate School of Medicine, Kyoto,
11	Japan
12	³ Department of Artificial Intelligence in Healthcare and Medicine, Kyoto University Graduate School
13	of Medicine, Kyoto, Japan
14	⁴ Kyoto University Faculty of Medicine, Kyoto, Japan
15	
16	Correspondence:
17	Yohei Mineharu, MD, PhD
18	Department of Artificial Intelligence in Healthcare and Medicine, Kyoto University Graduate School
19	of Medicine, Kyoto, Japan
20	+81-75-751-3111
21	Email: mineharu@kuhp.kyoto-u.ac.jp

22 ABSTRACT

29

Background and Purpose: Glioblastoma is a highly aggressive brain tumor with limited
survival that poses challenges in predicting patient outcomes. The Karnofsky Performance Status
(KPS) score is a valuable tool for assessing patient functionality and contributes to the stratification of
patients with poor prognoses. This study aimed to develop a 6-month postoperative KPS prediction
model by combining clinical data with deep learning-based image features from pre- and postoperative
MRI scans, offering enhanced personalized care for glioblastoma patients.

Materials and Methods: Using 1,476 MRI datasets from the Brain Tumor Segmentation

Challenge 2020 public database, we pretrained two variational autoencoders (VAEs). Imaging features 30 from the latent spaces of the VAEs were used for KPS prediction. Neural network-based KPS 31 prediction models were developed to predict scores below 70 at 6 months postoperatively. In this 32 retrospective single-center analysis, we incorporated clinical parameters and pre- and postoperative 33 MRI images from 150 newly diagnosed IDH wild-type glioblastoma, divided into training (100 34 patients) and test (50 patients) sets. In training set, the performance of these models was evaluated 35 using the area under the curve (AUC), calculated through fivefold cross-validation repeated 10 times. 36 The final evaluation of the developed models assessed in the test set. 37

Results: Among the 150 patients, 61 had 6-month postoperative KPS scores below 70 and 89
scored 70 or higher. We developed three models: a clinical-based model, an MRI-based model, and a
multimodal model that incorporated both clinical parameters and MRI features. In the training set, the
mean AUC was 0.785±0.051 for the multimodal model, which was significantly higher than the
clinical-based model (0.716±0.059, P=0.038) using only clinical parameters and MRI-based model
(0.651±0.028, P<0.001) using only MRI features. In the test set, the multimodal model achieved an
AUC of 0.810, outperforming the clinical-based (0.670) and MRI-based (0.650) models.

45 **Conclusion:** The integration of MRI features extracted from VAEs with clinical parameters in the

multimodal model substantially enhanced KPS prediction performance. This approach has the
 potential to improve prognostic prediction, paving the way for more personalized and effective
 treatments for patients with glioblastoma.

49 Abbreviations:

- 50 KPS, Karnofsky performance status. IDH, isocitrate dehydrogenase. VAE, variational autoencoder.
- 51 BraTS, Brain Tumor Segmentation challenge

52 Disclosure of potential conflicts of interest:

⁵³ The authors declare no conflicts of interest related to the content of this article.

55 INTRODUCTION

56	Glioblastoma is a highly malignant brain tumor with a median overall survival of
57	approximately 15-18 months.[1] Despite numerous studies on treatment strategies, it often recurs
58	rapidly, leading to a worsened functional prognosis.

Deep learning has increasingly been applied to detect, diagnose, and predict clinical outcomes in patients with glioblastoma.[2] However, it is still uncertain whether a radiomics approach using deep learning approach can enhance the prediction of clinical outcome or if pre- and postoperative MRI features can reliably predict prognosis.

The Karnofsky Performance Status (KPS) score stands as a robust independent predictor of 63 clinical outcomes within diverse oncology populations affected by malignant tumors.[3] A KPS score 64 of 70 indicates the patient can care for themselves but is unable to carry out daily activities. Among 65 patients with glioblastoma, multiple studies have indicated a correlation between a KPS score of <70 66 and a poor prognosis.[4] The 6-month postoperative KPS was chosen for its clinical practicality, as it 67 aligns with the standard timeframe for evaluating disease progression after a typical course of adjuvant 68 treatments. Predicting the postoperative KPS, along with the early identification of patients at risk of 69 diminished KPS in the postoperative stage, could lead to improved counseling and more personalized 70 clinical decision-making.[5] 71

In this study, we developed a multimodal model using clinical parameters and brain MRI to stratify patients into prognostic groups based on their 6-month postoperative KPS. We utilized a deep learning approach to extract imaging features from pre- and postoperative MRI images and investigated their prognostic value.

76

77 MATERIALS AND METHODS

The overall study process is illustrated in Fig 1. The proposed algorithm comprises two

primary stages: 1) constructing variational autoencoders (VAEs) to extract the reduced latent features
from the pre- and postoperative MRI images, and 2) developing a KPS prediction model by combining
the patients' clinical parameters and extracted imaging features. The authors collected patients' data
from April 2022 to July 2023.

Fig 1. Outline of the main steps in this study.

(1) Patient surveys and data acquisition from our institute's medical records, (2) brain tumor
segmentation using pre- and postoperative MRI, (3) imaging feature extraction using a pretrained
variation autoencoder combined with a convolutional neural network, and (4) prediction model
development using a neural network and training. The performance metrics in the training set were
evaluated using 10 repetition of fivefold cross-validation. GBM=glioblastoma; HGG=high-grade
glioma; VAE=variational autoencoder.

90

91 Ethics Approval

The Ethics Committee of Kyoto University Hospital approved this study (R2088). Verbal informed consent was obtained from the study participants. Participants were informed before their surgery that their images and clinical information would be used in a retrospective review after being fully anonymized. The ethics committee waived the requirement for written informed consent owing to the retrospective study design. Patients who did not wish to participate were excluded via an opt-out process.

98

99 **Patients**

This single-center retrospective review was conducted between December 2001 and December 2022 at our institution. This study included consecutive adult patients aged 18 years and older who were newly histopathologically diagnosed with glioblastoma with isocitrate dehydrogenase (IDH) wild type. The exclusion criteria for the study cohort were as follows: 1) gliomas that were not

histopathologically diagnosed as glioblastomas, 2) lack of immunohistochemical testing for the IDH1 104 R132H mutation or absence of IDH2 sequencing, 3) a diagnosis of IDH-mutant gliomas, and 4) a 105 follow-up period of <6 months. A total of 257 patients were pathologically confirmed to have 106 glioblastoma. Among these, 87 patients were excluded based on the following criteria: diagnosis of 107 IDH-mutant gliomas (n=11) or absence of either immunohistochemistry for the IDH1 R132H 108 mutation or IDH2 sequencing (n=76). Additionally, patients lacking sufficient medical records or 109 imaging data (n=18) and those aged <18 years (n=2) were also excluded. Subsequently, patients were 110 divided into training and test sets based on their first operation date. Patients who underwent surgery 111 from December 2001 to October 2018 were assigned to the training set, while those from November 112 2018 to December 2022 were included in the test set. This process resulted in 100 patients in the 113 training set and 50 in the test set (S1 Fig). 114

115 Clinical Parameters and Endpoints

The clinical parameters included following 28 variables.

Preoperative variables: sex, age at diagnosis, dominant hand (right/left), epilepsy (yes/no),
aphasia (yes/no), paralysis (yes/no), other neurological findings at onset (yes/no), and preoperative
KPS score (%).

Intraoperative variables: surgical strategy (biopsy or tumor removal), awake surgery (yes/no), 120 utilization of 5-aminolevulinic acid (yes/no), photodynamic therapy (yes/no), carmustine wafer 121 placement (yes/no), and motor-evoked or somatosensory-evoked potential monitoring (yes/no). 122 Immunohistochemical and genetic variables: O-6-methylguanine-DNA methyltransferase 123 (MGMT) methylation (positive/negative), TERTp alteration (positive/negative), MIB-1 labeling index 124 (%), and immunohistochemical staining for MGMT (positive/negative). 125 Postoperative variables: TMZ chemotherapy (yes/no), bevacizumab chemotherapy (yes/no), 126 radiation dose (Gy), number of radiation fractionations (Fr). 127 Radiological findings: tumor laterality (right/left/bilateral), ependymal involvement (yes/no), 128

129	midline shift (yes/no), corpus callosum invasion (yes/no), necrotic or cystic area evident on imaging
130	(yes/no), and extent of resection (1-49%, 50-89%, 90-99%, 100%).

11

Additionally, the 6-month postoperative KPS (%) score, the main endpoint of this study, was
collected.

For the standard concurrent chemoradiotherapy regimen, patients received fractionated focal radiation therapy with a cumulative dose of 60 Gy, accompanied by concomitant TMZ chemotherapy.[6] For elderly patients aged 70 years or older, a hypofractionated radiotherapy schedule of 40 Gy delivered in 15 fractions over 3 weeks was employed.[7] All patients were followed up every 1–2 months after surgical treatment.

138

139 Imaging Acquisition and Preprocessing

The following 3-mm slices of MRI scans were collected from each patient: T1WI, contrastenhanced T1W (T1Gd), ADC, DWI, and FLAIR. In the study population, preoperative MRI images were acquired within 2 weeks before surgery, and postoperative MRI images were acquired the day after surgery, whenever the patient's condition allowed. Brain MRI images were processed using a deep brain extractor to remove the skin and cranial bones.[8] The brain parenchyma was extracted based on the T1WI and DWI images (represented in gray in Fig 2).

146

147 **Tumor Segmentation**

1.0 (

· 11 ·

To achieve semantic segmentation of the glioblastoma lesion on MRI scans, we utilized a segmentation model based on the U-net architecture, specifically designed for the segmentation of glioma.[9] Using this segmentation model, we highlighted the segmented regions, including enhanced tumors, necrosis, and cystic lesions, which are shown in red. Peritumoral edema and non-enhancing tumor areas are shown in green (Fig 2). Images with a thickness of 3 mm were used for each MRI sequence. After semantic segmentation, the tumor area, represented in red, was automatically 154 measured. We then selected 24 segmented images per patient to ensure that the slice with the largest 155 tumor area was included in the central part of the selected slices.

156 Fig 2. Tumor segmentation using preoperative and postoperative MRI.

Using a pretrained U-net-based segmentation module, pre- and postoperative segmented images were
generated from 24 slices of FLAIR, T1W, T1Gd, ADC, and DWI images. The brain parenchyma is
displayed in gray, enhanced tumor lesions and necrosis in red, and peritumoral edema and nonenhancing lesions in green. T1Gd=contrast-enhanced T1W.

161

162 MRI Feature Extraction from the Latent Space of a Variational

163 Autoencoder

MRI features were extracted from the segmented brain images using two independently developed VAEs, as shown in Fig 3. VAE 1 was utilized to process segmented tumor lesions from pre- and postoperative MRI images as input data. In contrast, VAE 2 processed data from pre- and postoperative brain parenchyma areas, serving as both input and output. The comprehensive architecture of these VAEs is demonstrated in S2 Fig. From these VAEs, MRI features were extracted from the 48-dimensional latent spaces of both VAE 1 and 2.

170 Fig 3. Extraction of deep imaging features from the latent space of a variational autoencoder.

171 Twenty-four slices of the segmented images were separated into tumor lesions (red or green) and brain

mask images (gray). The tumor lesion images were processed by VAE 1, where internal 3D

convolutional neural networks extracted features and reduced dimensionality using encoder 1. As a

result, a 48-dimensional latent space was formed, and the generated deep imaging features were

- incorporated into the KPS prediction model. Similarly, the brain mask images were processed by
- being input into VAE 2. Both VAEs 1 and 2 were pretrained using the BraTS 2020 dataset.
- 177 VAE=variational autoencoder; KPS=Karnofsky performance status; BraTS=brain tumor segmentation
- 178 challenge.

We pretrained these VAEs using 1,476 MRI datasets of high-grade glioma and glioblastoma MRI images from the BraTS 2020 dataset.[10] BraTS 2020 provided thin-slice MRI images of 369 patients with high-grade gliomas. The slices were extracted at regular intervals to create four different MRI datasets from a single patient. Pretraining of the VAE was conducted using annotated brain mask images and segmented tumor regions as ground truth data (Fig 1).

185

186 Development of a KPS Prediction Model Using Neural Networks

To stratify patients with a postoperative KPS score of <70 at 6 months, we developed neural
network prediction models using training set (Fig 1).

These prediction models use two distinct inputs: clinical and MRI features. First, we developed a clinical neural network model using clinical parameters. In this clinical-based model, the input consists of clinical features, while the final output layer comprises two neurons, making it suitable for binary classification: predicting whether the 6-month postoperative KPS score <70 or ≥ 70 .

In addition to the clinical-based model, an MRI-based model was constructed using MRI
 features. Furthermore, clinical and accompanying MRI features were employed as inputs for the
 multimodal model. The details of the development of the prediction model are shown in S3 Fig.

During the model development with the training set, we assessed predictive performance using 196 the area under the receiver operating characteristic curve (AUC) through 10 repetitions of fivefold 197 cross-validation (Fig 1). This approach served as an appropriate internal validation procedure, 198 especially given the absence of external testing.[11,12] The effectiveness of the model was visualized 199 through the mean ROC curves across all fivefold cross-validation. Furthermore, to evaluate the 200 performance in fivefold cross-validation, the following metrics were computed: accuracy, sensitivity, 201 specificity, and F1 score. The performance of the three developed models-clinical-based, MRI-202 based, and multimodal—was evaluated using test sets that were held out during the model 203

development and training process. We also developed the following machine learning models: a
Random Forest classifier, XGBoost, and LightGBM. These machine learning models perform
hyperparameter tuning using the GridSearch software. We extensively compared and analyzed the
predictive capabilities of each classifier by considering the aforementioned metrics (S4 Fig).

208

209 Model Interpretability

Grouped permutation feature importance was utilized to determine the feature importance in 210 the neural network-based prediction model.[13] In this analysis, features were optionally grouped into 211 expert-defined subgroups, and a systematic assessment of their importance was conducted. In this 212 study, during the feature extraction process, 196 MRI features were generated from preoperative and 213 postoperative MRI imaging. To enhance interpretability, the variables derived from the preoperative 214 brain mask image were grouped as "pre mask variables". Similarly, variables from postoperative brain 215 mask, preoperative tumor lesion, and postoperative tumor lesion images were grouped as 216 "post mask," "pre lesion," and "post lesion variables," respectively. Twenty-eight clinical parameters 217 were evaluated separately, without grouping. 218

219

220 Statistical Analysis

All statistical analyses were performed using the SciPy library. Univariate analysis was used to examine the relationship between the 6-month postoperative KPS deterioration and clinical parameters. Fisher's exact test was used to evaluate categorical variables, whereas the Mann–Whitney U test was used for continuous variables. The cross-validated metrics of each prediction model were compared using the paired-samples t test. Statistical significance was set at P <0.05.

226

227

228 **RESULTS**

229 Patient Demographics

230	Of the 150 study population, 61 patients had a 6-month postoperative KPS score of <70 and 89
231	had \geq 70. Baseline clinical parameters are presented in Table 1. Among these 150 patients, 65 (43.3%)
232	were female, with a mean age of 64 years (range, 21–92 years). The median preoperative and 6-month
233	postoperative KPS scores were 80 (range, 20–100) and 70 (range, 0–100), respectively. Out of the 118
234	patients with a preoperative KPS score of \geq 70, 43 had a 6-month postoperative KPS score of <70.
235	Conversely, among the 38 patients with a preoperative KPS score of <70, 14 had a 6-month
236	postoperative KPS score of \geq 70. These patients were divided into training and test sets. Patients who
237	underwent surgery from December 2001 to October 2018 were assigned to the training set (n=100),
238	while those from November 2018 to December 2022 were included in the test set (n=50).

	Overall (N=150)	KPS < 70 (n=61)	KPS ≥ 70 (n=89)	P value
Sex (female), n (%)	65 (43.3)	24 (39.3)	41 (46.1)	0.50
Median age, year (range)	64 (21 – 92)	72 (32 – 92)	60 (21 - 83)	< 0.001
Dominant hand (right-handed), n (%)	147 (98)	58 (95.1)	89 (100)	0.07
Preoperative epilepsy, n (%)	40 (26.7)	12 (19.7)	28 (31.5)	0.13
Preoperative aphasia, n (%)	42 (28)	24 (39.3)	18 (20.2)	0.02
Preoperative paralysis, n (%)	67 (44.7)	35 (57.4)	32 (36.0)	0.01
Other preoperative neurological findings, n (%)	102 (68)	45 (73.8)	57 (64.0)	0.22
Operation strategy (biopsy), n(%)	27 (18)	20 (32.8)	7(7.9)	< 0.001
Awake surgery, n (%)	54 (36)	19 (31.1)	35 (39.3)	0.39
5-aminelevulinic acid (5-ALA), n (%)	78 (52)	25 (41.0)	53 (59.6)	0.03
Photodynamic therapy, n (%)	7 (4.7)	1 (1.6)	6 (6.7)	0.24
Carmustine wafers placement, n(%)	36 (24)	9 (14.8)	27 (30.3)	0.03

239 Table 1. Baseline clinical characteristics.

MEP or SEP monitoring, n (%)	76 (50.1)	26 (42.6)	50 (56.2)	0.14
Temozolomide chemotherapy, n (%)	142 (94.7)	56 (91.8)	86 (89.9)	0.27
Bevacizumab chemotherapy, n (%)	65 (43.3)	32 (52.5)	33 (37.1)	0.068
MGMT promoter methylation, n (%)	51 (34)	19 (31.1)	32 (36.0)	0.60
TERT promoter mutation, n (%)	49 (32.7)	19 (31.1)	30 (33.7)	0.86
Median MIB-1 index, % (range)	22.5 (0 - 90)	21.2 (10 - 80)	24.8 (0 - 90)	0.45
IHC staining of MGMT, n (%)	54 (36)	20 (32.8)	34 (38.2)	0.60
Radiation dose, Gy (range)	60 (0 - 63.2)	40.05 (0 - 60)	60 (0 - 63.2)	< 0.001
Number of radiation fraction (Fr)	30 (0 - 30)	15 (0 - 30)	30 (0 - 30)	< 0.001
Tumor laterality, n (%)				
Right	75 (50)	27 (44.3)	48 (53.9)	0.47
Left	63 (42)	28 (45.9)	35 (39.3)	-
Bilateral	12 (8.0)	6 (9.8)	6 (6.7)	-
Ependymal invasion, n (%)	107 (71.3)	51 (83.6)	56 (62.9)	0.006
Midline shift, n (%)	63 (42)	29 (47.5)	34 (38.2)	0.31
Corpus callosum invasion, n (%)	41 (27.3)	24 (39.3)	17 (19.1)	0.009
Necrosis/cysts evident on imaging, n (%)	138 (0.92)	58 (95.1)	80 (89.9)	0.36
Extent of resection, n (%)				
1-49%	30 (20)	22 (36.7)	8 (9.0)	< 0.001
50-89%	21 (14)	12 (19.7)	9 (10.1)	-
90–99%	43 (28.7)	10 (16.4)	33 (37.1)	-
100%	56 (37.3)	17 (27.9)	39 (43.8)	-
Karnofsky performance status				
Median preoperative KPS, (range)	80 (20 - 100)	70 (20 – 100)	80 (40 - 100)	< 0.001
Preoperative KPS ≥ 70, n (%)	118 (78.7)	43 (70.5)	75 (84.3)	0.002
Median 6-months postoperative KPS, (range)	70 (0 - 100)	50 (0 - 60)	80 (70 - 100)	< 0.001

240 Categorical variables are presented as the count of patients (percentage), while continuous variables

241 are shown as the median value (range).

MEP, motor evoked potentials. SEP, Somatosensory evoked potentials. MGMT, O-6-MethylguanineDNA Methyltransferase. TERT, Telomerase Reverse Transcriptase. IHC, Immunohistochemical. KPS,
Karnofsky performance status.

245

246

247 Model Development

Using the training set, we developed three models to predict 6-month postoperative KPS scores of <70: a clinical-based model, an MRI-based model, and a multimodal model that incorporated both MRI features and clinical data. When both clinical and MRI data were utilized, the area under the curve (AUC) was higher than when using either clinical or MRI data alone (Fig 4A–C, E). The mean AUC was 0.785 (SD 0.051) for the multimodal model using both clinical and MRI features, 0.716 (SD 0.059, P<0.001) when only clinical parameters were considered, and 0.651 (SD 0.028, P<0.001) when only MRI features were used.

Fig 4. Development of models to predict 6-month postoperative KPS score of <70 using the training set.

During model development, performance was evaluated using the training set with 10 repetitions of 257 fivefold cross-validation. The ROC curves for each repeat of the fivefold cross-validation are 258 represented in gray, whereas the mean ROC curve for the 10 repeats is shown in blue. The area under 259 the curve of the model was 0.715 when using clinical parameters (A), 0.651 when using deep imaging 260 features from pre- and postoperative MRI (B), and 0.785 when combining clinical parameters with 261 deep imaging features (C). (D) The top five feature contributions in the multimodal model are 262 evaluated by grouped permutation importance. (E) The predicted performance of each model. Data are 263 shown as the mean score \pm standard deviation. 264

265 KPS=Karnofsky performance status.

267	Multimodal models also outperform clinical-based and MRI-based models in terms of
268	accuracy (clinical parameters plus MRI features: 0.728 [SD 0.032]; clinical parameters: 0.674 [SD
269	0.045, P<0.021]; MRI features: 0.631 [SD 0.021, P<0.001]), sensitivity (clinical parameters plus MRI
270	features: 0.529 [SD 0.091]; clinical parameters: 0.406 [SD 0.117, P=0.039]; MRI features: 0.402 [SD
271	0.076, P=0.01]), and F1 score (clinical parameters plus MRI features: 0.572 [SD 0.066]; clinical
272	parameters: 0.434 [SD 0.086, P=0.002]; MRI features: 0.439 [SD 0.078, P=0.005]). The specificity of
273	the multimodal model was 0.847 [SD=0.057], which was not significantly different from the clinical-
274	based model (0.834, [SD=0.115, P=0.77]) and the MRI-based model (0.789, [SD=0.042, P=0.06]).

The neural network-based prediction model outperformed other machine learning classifiers, 275 including the Random Forest classifier, XGBoost, and LightGBM, when utilizing clinical parameters 276 and MRI features. The mean AUC scores, determined through 10 repeated fivefold cross-validations 277 with optimized hyperparameters, were calculated for each classifier. The mean AUC scores and 278 associated P values compared with the neural network model were as follows: Random Forest 279 classifier, 0.663 (SD 0.020, P<0.001); XGBoost, 0.705 (SD 0.029, P<0.005); and LightGBM, 0.720 280 (SD 0.23, P=0.01) (S4 Fig). Moreover, the test set evaluation of our neural network models-clinical-281 based, MRI-based, and multimodal-demonstrated the superiority of the multimodal model with the 282 mean AUC of 0.810. Its performance metrics included accuracy of 0.727, specificity of 0.643, 283 sensitivity of 0.789, and an F1 score of 0.76, mirroring the training set outcomes (Fig 5). 284

Fig 5. Prediction performance in the test set

The clinical-based, MRI-based, and multimodal models were pretrained using the training set, then their prediction performance was evaluated using the test set.

288

289 Model Interpretability Analysis

To improve the understanding, trust, and verification of the model predictions, grouped permutation importance was applied.[13] Grouped permutation importance quantifies the feature contribution, thus providing an interpretable relationship between the incorporated features and the model prediction. Fig 4D illustrates the importance of the top five relative features for the multimodal
model to predict a 6-month KPS score of <70. The most important feature in the model was "age,"
followed by "radiation dose (Gy)" and "preoperative KPS." Furthermore, "postoperative mask image"
ranked fourth, while "preoperative mask image" ranked fifth, and these MRI features also contributed
to the model prediction.

298

299 **DISCUSSION**

Improved Performance When Incorporating Multimodal Data

The current study demonstrated that combining imaging features with clinical parameters is 301 effective in improving the performance of clinical-based models, leading to the construction of 302 clinically implementable models. There has been a notable increase in machine learning-based models 303 to solve medical challenges in glioblastoma[14]; however, these models typically use data from only 304 one modality (e.g., clinical parameters). Recently, several researchers have successfully improved the 305 performance of models designed for clinical implementation by combining multiple modalities rather 306 than relying on a single modality.[15] To construct a multimodal model incorporating medical 307 imaging data into clinical-based models, it is necessary to extract imaging features from the 308 radiographic images. The imaging features used in this process can be broadly categorized into two 309 types: handcrafted and deep imaging features.[16] In general, handcrafted features are defined by the 310 use of explicit formulas and are often derived from morphological, statistical, and textural properties. 311 On the other hand, deep imaging features are generated through a deep learning using transfer 312 learning.[17] 313

Lao et al. examined the importance of deep imaging and handcrafted features in the development of an overall survival prediction model for 112 patients with glioblastoma.[16] They compared 1,403 handcrafted features with 98,304 deep imaging features, which were extracted using a convolutional neural network from the preoperative MRIs. They concluded that deep imaging features contributed more to the model's performance. Recently, reviewing 69 studies of radiomic models,
Demircioglu reported that clinical-based models constructed based on deep imaging features often
outperform those relying on handcrafted features. Additionally, the author suggested that combining
the two into a fused model could potentially enhance model performance.[17] When processing threedimensional MRI data using a pretrained convolutional neural network, a very large number of
features were generated compared to the number of patients. Therefore, strong feature selection and
shrinkage are required to develop reliable clinical-based models and increase interpretation.[18]

In the present study, we utilized a VAE as a feature extractor and demonstrated significant 325 improvements in the performance of the KPS prediction model for patients with glioblastoma. Deep 326 imaging features (i.e., MRI features) were extracted from the latent space and subsequently combined 327 with clinical parameters. When jointly trained on data from MRI and clinical parameters in the 328 training set, the mean AUC for predicting a 6-month postoperative KPS score of <70 was consistently 329 higher (0.785, SD 0.051) than the models trained solely on clinical parameters (0.716, SD 0.059, 330 P=0.038) or MRI features (0.651, SD 0.028, P<0.001) (Fig 4E). Furthermore, in the test set, the 331 multimodal model's AUC was 0.810, surpassing the clinical-based model's AUC of 0.670 and the 332 MRI-based model's AUC of 0.650 (Fig 5). The important features contributing to the development of 333 the combined model were evaluated using group permutation importance.[13] Among the top five 334 important features, three clinical parameters, namely "age," "radiation dose," and "preoperative KPS," 335 were included, along with the deep imaging features extracted from MRI, "postoperative mask image," 336 and "preoperative mask image." Analysis of grouped permutation importance supported the idea that 337 MRI features contributed to model development and improved model performance. We consistently 338 observed an improvement in prediction performance when incorporating clinical parameters and MRI 339 features. This aligns with findings from other studies that have utilized deep learning models to merge 340 diverse data modalities, including scenarios where clinical parameters were integrated with chest X-341 rays or cancer biomarkers were fused with MRI data.[19,20] The integration of medical imaging data 342 with corresponding medical parameters is proving to be a valuable approach for enhancing model 343 performance. 344

345

346 Clinical Implication

Prediction of health status and functional impairment is critical for clinical and personal
decision-making in patients with glioblastoma. A KPS score of ≥70 indicated that the patients were
capable of independent self-care. Identifying patients who will require nursing or caregiving 6 months
postoperatively or patients who are currently in need of care but are expected to recover independent
living within 6 months is crucial for providing personalized medical management.

A low KPS was significantly correlated with a poor prognosis. For patients presenting with a 352 353 KPS score of <70, less invasive treatments may be considered as an alternative to the standard protocol, which generally includes tumor removal followed by chemoradiotherapy.[21] A recent 354 retrospective analysis revealed that the mean overall survival for patients with a postoperative KPS 355 score of <70 was 8 months.[4] Moreover, in clinical practice, when managing recurrent glioblastoma, 356 their performance status can significantly influence therapeutic decision-making, which may involve 357 options like surgical re-intervention, re-irradiation, or best supportive care.[22] Due to the limited 358 availability of publicly accessible, precise clinical databases, research predicting the course of 359 performance status in patients with malignant tumors is much scarcer compared to the development of 360 prediction models for overall survival or progression-free survival. However, in recent years, several 361 studies have reported that machine learning approaches have successfully predicted changes in KPS 6 362 months postoperatively in patients with glioblastoma, as well as poor performance status in patients 363 with cancer 6 months after diagnosis. [23,24] The development of a KPS prediction model could help 364 stratify patients based on their anticipated clinical course, resulting in significant implications for 365 optimizing the balance between preserving quality of life and pursuing a more aggressive treatment 366 approach. 367

The prediction of prognosis using pre- and postoperative MRI may also contribute to surgical planning. The planning and outcome of brain tumors are influenced by the surgeon's experience and involve weighing the benefits of resection against the risk of neurological impairment.[25] It has recently been reported that preoperative T1Gd MRI images can accurately predict surgical
resectability using a neural network.[26] Furthermore, a recent study has demonstrated that generative
artificial intelligence models are capable of producing fine-quality images of brain tumors and normal
parenchyma.[27] We assumed that the present KPS prediction model could enhance surgical
simulation when integrated with a reliable surgical resectability prediction model and by using
generative artificial intelligence to produce postoperative MRI images from preoperative scans.

377 Limitations

This study was limited by its relatively small patient cohort. Therefore, well-powered studies 378 are required. As a retrospective study conducted at a single center, its external validity may have been 379 limited by patient selection bias in our department. In accordance with the previously reported critical 380 appraisal guidelines for AI research, our study aligns with Level 5B: one retrospective study with only 381 internal data used for final performance reporting.[28] Our understanding of surgical techniques and 382 adjuvant therapy has gradually evolved. Patients treated in the latter years of this study likely benefited 383 from our greater knowledge and improved treatments that are not included as clinical parameters in 384 this study. 385

386

387 CONCLUSIONS

Imaging features extracted from MRI scans using VAEs may provide valuable representations reflecting the prognosis of patients with wild-type IDH glioblastoma. The integration of these imaging features, achieved through the development of a multimodal model, significantly enhanced the performance of the neural network-based prediction model. Predicting the 6-month postoperative KPS score has the potential to impact personalized treatment decisions, including the selection of treatment intensity and consideration of early palliative care. The future clinical implementation of the KPS prediction model offers the possibility of tailored medical interventions.

Authors' contributions 396

416

397	Conception and design: Tomoki Sasagasako, Yohei Mineharu, Akihiko Ueda; Acquisition of
398	data: Tomoki Sasagasako, Yohei Mineharu; Analysis and interpretation of data: Tomoki Sasagasako,
399	Yohei Mineharu, Akihiko Ueda, Yasushi Okuno; Drafting the article: Tomoki Sasagasako; Critically
400	revising the article: Akihiko Ueda, Yohei Mineharu, Yoshiki Arakawa, Yasushi Okuno;
401	Administrative/technical/material support: Yusuke Mochizuki, Souichiro Doi, Silsu Park, Yukinori
402	Terada, Noritaka Sano, Masahiro Tanji; Study supervision: Yasushi Okuno and Yoshiki Arakawa;
403	Approval of the final version of the manuscript: all authors.
404	
405	Code availability
406	The code used to develop the model described herein is publicly available on GitHub:
407	https://github.com/TomokiSasagasako/GBM_KPS_prediction.git
408	The clinical data in this study are available, on reasonable request, from the corresponding author.
409	
410	Funding
411	This work was supported by the Ministry of Education, Culture, Sports, Science, and
412	Technology (MEXT) under the RIKEN joint research and collaboration fund for "Translational
413	Research in Basic and Clinical Sciences for the Construction of an AI Pharmaceutical Platform".
414	
415	
416	REFERENCES

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of 1. 417 radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on 418 survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC 419

420		trial. Lancet Oncol. 2009;10: 459-466. doi:10.1016/S1470-2045(09)70025-7
421	2.	Wankhede DS, Selvarani R. Dynamic architecture based deep learning approach for
422		glioblastoma brain tumor survival prediction. Neurosci Informatics. 2022;2: 100062.
423		doi:10.1016/j.neuri.2022.100062
424	3.	West H, Jin JO. Performance status in patients with cancer. JAMA Oncol. 2015;1: 998.
425		doi:10.1001/jamaoncol.2015.3113
426	4.	Barz M, Gerhardt J, Bette S, Aftahy AK, Huber T, Combs SE, et al. Prognostic value of tumour
427		volume in patients with a poor Karnofsky performance status scale - a bicentric retrospective
428		study. BMC Neurol. 2021;21: 1–10. doi:10.1186/s12883-021-02424-0
429	5.	Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable
430		prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD Statement.
431		BMC Med. 2015;13: 1–10. doi:10.1186/s12916-014-0241-z
432	6.	Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant
433		temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008;88: 97-103.
434		doi:10.1007/s11060-008-9538-0
435	7.	Roa W, Brasher PMA, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of
436		radiation therapy in older patients with glioblastoma multiforme: A prospective randomized
437		clinical trial. J Clin Oncol. 2004;22: 1583-1588. doi:10.1200/JCO.2004.06.082
438	8.	Kleesiek J, Urban G, Hubert A, Schwarz D, Maier-Hein K, Bendszus M, et al. Deep MRI brain
439		extraction: A 3D convolutional neural network for skull stripping. Neuroimage. 2016;129: 460-
440		469. doi:10.1016/j.neuroimage.2016.01.024
441	9.	Kermi A, Mahmoudi I, Khadir MT. Deep convolutional neural networks using U-Net for
442		automatic brain tumor segmentation in multimodal MRI volumes. In: Crimi A, Bakas S, Kujif
443		S, Keyvan F, Reyes M, van Walsum T, eds. Brain lesion: glioma, multiple sclerosis, stroke and
444		traumatic brain inju. 2019;11384. doi:10.1007/978-3-030-11726-9
445	10.	Bakas S, Reyes M, Jakab A, Bauer S, Rempfler M, Crimi A, et al. Identifying the Best Machine

446		Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall
447		Survival Prediction in the BRATS Challenge. 2018. Available: http://arxiv.org/abs/1811.02629
448	11.	Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al.
449		Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis
450		(TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162: W1-W73.
451		doi:10.7326/M14-0698
452	12.	Rodríguez JD, Pérez A, Lozano JA. Sensitivity analysis of k-fold cross validation in prediction
453		error estimation. IEEE Trans Pattern Anal Mach Intell. 2010;32: 569–575.
454		doi:10.1109/TPAMI.2009.187
455	13.	Plagwitz L, Brenner A, Fujarski M, Varghese J. Supporting AI-Explainability by Analyzing
456		Feature Subsets in a Machine Learning Model. Stud Health Technol Inform. 2022;294: 109-
457		113. doi:10.3233/SHTI220406
458	14.	Valdebenito J, Medina F. Machine learning approaches to study glioblastoma: a review of the
459		last decade of applications. Cancer Rep. 2019;2: 1-15. doi:10.1002/cnr2.1226
460	15.	Huang SC, Pareek A, Seyyedi S, Banerjee I, Lungren MP. Fusion of medical imaging and
461		electronic health records using deep learning: a systematic review and implementation
462		guidelines. NPJ Digit Med. 2020;3. doi:10.1038/s41746-020-00341-z
463	16.	Lao J, Chen Y, Li ZC, Li Q, Zhang J, Liu J, et al. A Deep learning-based radiomics model for
464		prediction of survival in glioblastoma multiforme. Sci Rep. 2017;7: 1-8. doi:10.1038/s41598-
465		017-10649-8
466	17.	Demircioğlu A. Are deep models in radiomics performing better than generic models? A
467		systematic review. Eur Radiol Exp. 2023;7. doi:10.1186/s41747-023-00325-0
468	18.	Zhang X, Maltbie EA, Keilholz SD. Spatiotemporal trajectories in resting-state FMRI revealed
469		by convolutional variational autoencoder. Neuroimage. 2021;244: 105-124.
470		doi:10.1016/j.neuroimage.2021.118588
471	19.	Reda I, Khalil A, Elmogy M, El-Fetouh AA, Shalaby A, El-Ghar MA, et al. Deep learning role

in early diagnosis of prostate cancer. Technol Cancer Res Treat. 2018;17: 1–11.

473 doi:10.1177/1533034618775530

- Khader F, Müller-Franzes G, Wang T, Han T, Tayebi Arasteh S, Haarburger C, et al.
 Multimodal deep learning for integrating chest radiographs and clinical Parameters: a case for
 transformers. Radiology. 2023;309: e230806. doi:10.1148/radiol.230806
- 477 21. McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: Clinical presentation,
 478 diagnosis, and management. BMJ. 2021;374. doi:10.1136/bmj.n1560
- Demogeot N, Salleron J, Rech F, Taillandier L, Royer P, Vogin G. Impact of fractionated
 stereotactic radiotherapy on activity of daily living and performance status in
- 481 progressive/recurrent glioblastoma: a retrospective study. Radiat Oncol. 2022;17: 1–9.
- 482 doi:10.1186/s13014-022-02169-1
- Della Pepa GM, Caccavella VM, Menna G, Ius T, Auricchio AM, Chiesa S, et al. Machine
 learning–based prediction of 6-month postoperative Karnofsky performance status in patients
 with glioblastoma: capturing the real-life interaction of multiple clinical and oncologic factors.
 World Neurosurg. 2021;149: e866–e876. doi:10.1016/j.wneu.2021.01.082
- Seow H, Tanuseputro P, Barbera L, Earle CC, Guthrie DM, Isenberg SR, et al. Development
 and validation of a prediction model of poor performance status and severe symptoms over time
 in cancer patients (PROVIEW+). Palliat Med. 2021;35: 1713–1723.
- 490 doi:10.1177/02692163211019302
- Ramakrishna R, Hsu WC, Mao J, Sedrakyan A. Surgeon annual and cumulative volumes
 predict early postoperative outcomes after brain tumor resection. World Neurosurg. 2018;114:
 e254–e266. doi:10.1016/j.wneu.2018.02.172
- Marcus AP, Marcus HJ, Camp SJ, Nandi D, Kitchen N, Thorne L. Improved prediction of
 surgical resectability in patients with glioblastoma using an artificial neural network. Sci Rep.
 2020;10: 1–9. doi:10.1038/s41598-020-62160-2
- 497 27. Mukherkjee D, Saha P, Kaplun D, Sinitca A, Sarkar R. Brain tumor image generation using an

498		aggregation of GAN models with style transfer. Sci Rep. 2022;12: 1-16. doi:10.1038/s41598-
499		022-12646-у
500	28.	Pham N, Hill V, Rauschecker A, Lui Y, Niogi S, Fillipi CG, et al. Critical Appraisal of
501		Artificial Intelligence Enabled Imaging Tools Using the Levels of Evidence System. Am J

502 Neuroradiol. 2023;44: E21–E28. doi:10.3174/ajnr.A7850

504 Supporting information

- 505 S1 Fig. Participants flow
- 506 S2 Fig. The architecture of the variational autoencoder
- 507 S3 Fig. The KPS prediction model development using neural network
- 508 S4 Fig. Comparison between the neural network and other machine learning algorithm

509



Fig1





Fig2







C. Multimodal model

D. Top 5 feature contributions in the multimodal model





E. Predictive performance of each model in the training set

Metrics	Clinical-based model	MRI-based model	Multimodal model	P value [†]	P value*
AUC	0.716 ± 0.059	0.651 ± 0.028	0.785 ± 0.051	0.038	<0.001
Accuracy	0.674 ± 0.045	0.631 ± 0.021	0.728 ± 0.032	0.021	<0.001
Specificity	0.834 ± 0.115	0.789 ± 0.042	0.847 ± 0.057	0.77	0.06
Sensitivity	0.406 ± 0.117	0.402 ± 0.076	0.529 ± 0.091	0.039	0.01
F1 score	0.434 ± 0.086	0.439 ± 0.078	0.572 ± 0.066	0.002	0.005

Mean score \pm Standard deviation

- † Multimodal model versus clinical-based model
- * Multimodal model versus MRI-based model



Metrics	Clinical-based model	MRI-based model	Multimodal model
AUC	0.670	0.650	0.810
Accuracy	0.660	0.540	0.727
Specificity	0.740	0.815	0.643
Sensitivity	0.565	0.217	0.789
F1 score	0.604	0.303	0.769

Fig5